At a Glance
A prostate cancer diagnosis can trigger anxiety and uncertainty. Patients often search online or speak to friends before meeting a specialist. This can expose them to outdated or misleading information.
Many prostate cancer myths “it’s only an old man’s disease” to “treatment always causes incontinence” are based on outdated care or individual anecdotes, and they can delay diagnosis or narrow treatment choice. Modern pathways combine PSA testing, pre-biopsy MRI, targeted biopsy and tissue-preserving options like HIFU (NICE IPG424) and NanoKnife IRE (NICE IPG768) can significantly reduce functional side effects in suitable men. The safest approach is evidence-based information from a multi-disciplinary specialist team.
Key Takeaways
- Not just older men – Family history and African/Caribbean heritage can raise risk under 50.
- Early cancer usually has no symptoms – PSA testing and MRI, not symptoms, find most cases.
- Modern PSA testing is different – Combined with MRI and target biopsy, it reduces overdiagnosis.
- Incontinence and erectile dysfunction are not inevitable – Focal therapy preserves function in the large majority of suitable patients. FTC audit, n = 265T
- Slow growing does not equal ignore – Active surveillance is a structured, evidence-based pathway with regular PSA, MRI, and biopsy testing.
Why tackling prostate cancer myths matters
Myth vs fact – common prostate cancer misconceptions
Prostate cancer myths and facts often become blurred in everyday conversations. Many misconceptions are based on older treatment approaches or individual experiences. Modern diagnostics and targeted therapies have changed the clinical landscape significantly over the past decade.
Below are common prostate cancer myths explained clearly.
Myth 1 – prostate cancer is an “old man’s disease”
Prostate cancer is more common in men over 50. However, it is not limited to elderly men. Younger men can also be diagnosed, particularly if there is a family history or if they are of Black African or Black Caribbean descent. Treatment decisions should reflect overall physiological health and life expectancy, not chronological age alone.
Myth 2 – prostate cancer always causes clear early symptoms
Many men assume cancer will inevitably cause obvious warning signs. In reality, early-stage prostate cancer often has no noticeable symptoms. The absence of pelvic pain or difficulty in urinating does not guarantee the absence of disease.
Some urinary changes may appear later, but these are frequently linked to benign prostatic hyperplasia rather than cancer. Understanding possible early symptoms supports timely testing and diagnosis before the disease progresses.
Myth 3 – the PSA test does more harm than good
PSA testing has been debated in the past. Earlier diagnostic pathways sometimes led to unnecessary biopsies or overtreatment.
Modern pathways now combine PSA testing with advanced imaging and targeted biopsy. This approach reduces overdiagnosis and improves accuracy. PSA testing remains an important first step when used appropriately.
Myth 4 – treatment will always cause incontinence and impotence
Concerns about side effects are common. Traditional whole-gland treatments such as radical surgery or radiotherapy can significantly affect urinary control and sexual function.
Minimally invasive treatments now offer different outcomes for suitable patients. Techniques such as focal therapy treat only the cancerous area, preserving healthy tissue where possible. Reported rates of incontinence and erectile dysfunction in experienced centres are significantly lower than with traditional surgery.
Myth 5 – if the cancer is slow-growing, it should be ignored
Some prostate cancers grow slowly. Slow-growing does not mean risk-free. Careful monitoring is essential to detect changes early.
Active surveillance is a structured and evidence-based approach. It involves regular PSA tests, MRI scans, and follow-up biopsies when required. This avoids unnecessary treatment while maintaining safety.
Myth 6 – every centre offers all options
Treatment availability varies significantly across hospitals and regional healthcare trusts. Not all centres possess the specialist equipment to offer tissue-preserving minimally invasive therapies.
Seeking a second opinion can clarify options. Preparing specific urologist questions and discussing validated decision-support tools ensures all suitable treatments are objectively considered.
Myth 7 – prostate cancer treatment ends once the procedure is over
Treatment is not the final step. Monitoring continues after therapy to assess PSA levels and detect any recurrence. Ongoing follow-up is part of safe long-term care.
Modern survivorship care focuses on physical recovery, sexual health, and emotional wellbeing. Structured personalised care and support planning improves long-term outcomes, addressing individual needs and restoring patient confidence.
Myth 8 – a diagnosis means cancer has already spread
Localised prostate cancer is confined to the prostate gland. Many men are diagnosed at this stage due to improved diagnostic pathways. Early detection supports effective and targeted treatment.
When detected early, outcomes are often very positive. Advances in imaging and biopsy techniques have improved staging accuracy significantly.
Why these myths persist
Misinformation spreads easily in the digital age. Personal stories shared online can be powerful but may not reflect current medical practice. Anecdotes often overshadow updated clinical data.
Outdated opinions also continue to circulate. Prostate cancer care has changed rapidly over the past decade. Some myths are based on treatments that are no longer standard practice.
Cost concerns contribute heavily to misunderstanding. Assumptions about the private prostate cancer treatment cost can prevent men from exploring highly effective options or seeking statutory financial support where available.
Medical language can also be highly distressing. Terms like “high-risk” or “carcinoma” may create fear without proper context. Clear explanations from specialists reduce this misinterpretation.
Why evidence-based information matters
Evidence-based information reduces fear. Patients who understand prostate cancer myths and facts are less likely to delay important decisions. Accurate knowledge improves treatment confidence.
Reliable data supports safe treatment selection. Choosing appropriate care reduces unnecessary harm and improves quality of life. Clear evidence also strengthens communication between patients and clinicians.
Adherence to follow-up appointments is higher when patients understand their purpose. This improves detection of recurrence and supports long-term success.
How to identify reliable prostate cancer information
Reliable clinical information invariably comes from peer-reviewed research and recognised specialist centres. Guidelines published by authoritative bodies such as the European Association of Urology (EAU), NICE, and the British Association of Urological Surgeons (BAUS) provide gold-standard data.
Be exceedingly cautious of internet forums offering direct medical advice. Individual experiences vary immensely and may not apply to every specific diagnosis. Treatment decisions require bespoke care guided exclusively by qualified specialists.
Red flags include miracle cure claims, pressure to act immediately, or advice without imaging confirmation.
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
Myths and modern prostate cancer care
Modern care actively challenges many long-standing prostate cancer myths. Imaging advancements now allow clinicians to visualise tumours accurately before any intervention.
Key developments in modern prostate cancer care include:
- Multiparametric MRI scans that improve tumour detection, accurately guide targeted biopsies, and support precise risk assessment prior to treatment.
- Multidisciplinary team (MDT) review, where urologists, oncologists, radiologists and pathologists assess each case collectively to determine the safest and most suitable treatment plan.
- Active surveillance protocols for carefully selected patients, offering structured monitoring with regular PSA tests, imaging, and follow-up appointments to prevent overtreatment.
- Minimally invasive treatments such as focal therapy, which aim to target only the cancerous portion of the prostate while preserving healthy tissue and reducing long-term side effects.
- Targeted management of recurrence, allowing selected patients to receive additional localised treatment where appropriate.
Over 90% of suitable patients treated show no clinically significant disease at one year following focal treatment at our clinic. Incontinence rates are reported at under 3%, with erectile dysfunction rates also below 3% at one year, also. Ongoing audits continue to refine these precision-based approaches and improve long-term outcomes.
How to talk about prostate cancer myths with your doctor
Patients should feel confident raising concerns during appointments. Writing down prostate cancer myths heard online helps structure the conversation. Clear discussion improves understanding.
Ask for evidence behind treatment recommendations. Request explanations of benefits, risks, and alternatives. Clarifying terminology reduces confusion.
Take notes during consultations. Bringing a partner or family member can provide additional support. Follow-up questions ensure decisions feel informed and balanced.
Support for patients and carers
Emotional and practical support plays a key role after diagnosis. Partners and families often experience anxiety alongside the patient. Access to professional support improves coping strategies.
Specialist nurses and counsellors provide structured support services. Peer groups and helplines allow patients to speak with others who share similar experiences. These conversations can reduce isolation.
Financial guidance may also be necessary. Understanding private prostate cancer treatment cost helps patients plan confidently, and some organisations offer financial support where needed. Clear information reduces additional stress during treatment planning.
FAQs
References
Cancer Research UK. (n.d.). Prostate cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer
Prostate Cancer UK. (2026). It’s a fact: prostate cancer now the most common cancer in the UK. Available at: https://prostatecanceruk.org/about-us/news-and-views/2026/01/prostate-most-common-cancer
National Institute for Health and Care Excellence. (2019, updated 2021). Prostate cancer: diagnosis and management (NG131). Available at: https://www.nice.org.uk/guidance/ng131
European Association of Urology. (2026). EAU Guidelines on Prostate Cancer. Available at: https://uroweb.org/guidelines/prostate-cancer
Public Health England, Cancer Research UK and Prostate Cancer UK. (2020). PSA testing and prostate cancer: advice for well men aged 50 and over. Available at: https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/PSA%20Advice.pdf
